Cholestasis of Parenteral Nutrition Clinical Trial
Official title:
Comparison of Composite Lipid Emulsion Containing Fish Oil to Soy-based Lipid Reduction for Cholestasis Prevention in Neonates Requiring Abdominal Surgery
Intestinal failure associated liver disease is a cholestatic liver disease associated with prolonged need for parenteral nutrition that can lead to such significant complications as liver failure. In the neonatal population, infants with history of intestinal resection and short bowel syndrome are at increased risk for this disease. The investigators plan to compare two possible lipid dosing preventative strategies including a composite, fish oil lipid and soy-based lipid reduction.
Intestinal failure associated liver disease (IFALD) is a cholestatic liver disease associated with prolonged need for parenteral nutrition. This disease can lead to such serious complications as liver failure and need for transplantation. In the neonatal population, short bowel syndrome, due to intestinal resection, is the most common cause of intestinal failure. While the exact cause is yet to be determined, it is felt the lipid component of parenteral nutrition is a large contributor to the development of this disease. Currently, there is no standard preventative strategy to attempt to decrease the risk of IFALD in the high risk, post-surgical neonatal population. The investigators aim to complete a randomized trial comparing two possible preventative strategies. One group will receive a composite lipid containing fish oil (Smoflipid) and the other group will receive soy-based lipid at reduced dosing. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00738101 -
Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
|
N/A | |
| Completed |
NCT03662282 -
Omegaven as Alternative Parenteral Fat Nutrition
|
Phase 3 | |
| Completed |
NCT02370251 -
Compassionate Use of Omegaven in Children
|
Phase 2/Phase 3 | |
| Completed |
NCT01072721 -
Non Invasive Study of the Hepatic Fibrosis in Paediatrics by the Method of Study of Pediatric Hepatic Fibrosis
|
N/A | |
| Recruiting |
NCT05043194 -
Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis
|
N/A | |
| Approved for marketing |
NCT01861834 -
Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
|